Nymox plans Phase III for BPH candidate
This article was originally published in Scrip
Executive Summary
Nymox Pharmaceutical has met the US FDA to discuss its upcoming Phase III programme for NX-1207 – the company's candidate for benign prostatic hyperplasia (BPH) – which will incorporate specific protocol design recommendations made by the agency.